Skip to content

U-100 unit conversion

Thymosin Beta-4 Fragment 1-4 calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

10U-100 units · 0.1 mL

25 mcg per unit · 2500 mcg/mL

How the calculator works, sources and review dates

Thymosin Beta-4 Fragment 1-4 math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 5 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-10. source-curated; clinician review pending.

Units chart for listed Thymosin Beta-4 Fragment 1-4 sizes

U-100 math for listed Thymosin Beta-4 Fragment 1-4 sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
5 mg502516.7
10 mg1005033.3

What is Thymosin Beta-4 Fragment 1-4?

Other names in the library: TB4 Frag 1-4, TB-500 Fragment 1-4, TB-500 Thymosin Beta-4 Fragment 1-4 — 10mg / Premium, TB-500 Thymosin Beta-4 Fragment 1-4 — 5mg / Premium. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: 5 mg, 10 mg. A seller title is a listing. It does not prove the vial matches a paper.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Regulatory context

Regulatory context; not efficacy evidence

No matched controlled clinical study of this exact preparation was verified in this source audit.

Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.

Nonresponse. Nonresponse frequency not established in this excerpt.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.

Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human trial

[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].

84 locally advanced, nonmetastatic head/neck or esophageal squamous-cell-carcinoma patients, 221 chemotherapy cycles; 83 evaluable after one early death.

Reported findings. No significant hematologic protection demonstrated in this randomized blinded placebo trial.

Nonresponse. No statistically significant difference in hematologic nadirs or toxicity duration was detected during carboplatin/fluorouracil co-treatment.

Harms. Anemia and lymphopenia were more frequent with goralatide despite favorable author tolerability wording. One early death occurred before evaluation; treatment attribution is unspecified.

Limits. Chemotherapy cycles are not independent patients. Favorable author tolerability language must remain alongside the reported hematologic harms. This preparation does not establish benefit or safety for an unspecified commercial fragment or other indication.

Preparation: Experimental goralatide; catalog SDKP/Ac-SDKP acetylation and preparation equivalence unverified. Route: Peptide route unspecified in abstract; fluorouracil intravenous administration does not establish goralatide route.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Identity context

Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSF.

Source identity support only; not an additional human trial cohort.

Reported findings. Supports the goralatide/AcSDKP name relationship, not efficacy of the catalog fragment.

Nonresponse. This identity record provides no population response-rate or trial-effect estimate.

Harms. Identity correspondence is not evidence of clinical safety.

Limits. This source is separate from the randomized human trial PMID8535033 and is not counted as independent trial efficacy evidence. Unacetylated SDKP and an unspecified supplier preparation are not silently equated to AcSDKP.

Preparation: Original paper names goralatide as AcSDKP; catalog fragment acetylation, chemistry and equivalence remain unverified. Route: No route inferred from this identity-support record.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Lab or animal research

The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism.

Normal human bone-marrow-derived primitive progenitors in adherent layers of long-term cultures; not treated patients.

Reported findings. No benefits established in the inspected original abstract; absence of reporting does not establish absence of an effect.

Nonresponse. Unacetylated SDKP did not inhibit proliferation of primitive normal progenitors in long-term-culture adherent layers in the tested comparator condition.

Harms. No harms established in the inspected original abstract; absence of reporting does not establish safety.

Limits. Single specified cultured-cell endpoint; no human clinical efficacy, exposure outcomes or safety established. Parent AcSDKP lowered S-phase cycling and affected colony formation in separate arms. These acetylated-compound results must not be assigned to unacetylated SDKP. Full methods, comparator end groups, purity and preparation provenance are not established from the accessible original abstract. Original publisher PDF unavailable. Original indexed abstract and raw metadata were reconciled; original article full-response hash remains null. No indexed correction/retraction link was returned in the fresh metadata; this is a bounded lifecycle check only. No SDKP-specific harms are established from the accessible abstract; not evidence of safety.

Preparation: Unacetylated SDKP comparator explicitly tested in original abstract, separately from NAc-Ser-Asp-Lys-Pro-OH (AcSDKP). SDKP end-group/purity details not established from abstract. Route: Added to long-term cell culture; no human administration route.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Compounding

not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.

Research

source limited. No matched controlled clinical study of this exact preparation was verified in this source audit.

Sport

unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.

Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

Risks and mix-ups already on the record

  • Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
  • No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
  • No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.

People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.

Sources

  1. Regulatory context; not efficacy evidence · checked 2026-10-09

Questions people ask

Is Thymosin Beta-4 Fragment 1-4 FDA-approved?

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Does PepBear pick an amount of Thymosin Beta-4 Fragment 1-4?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

How many units is a listed Thymosin Beta-4 Fragment 1-4 vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.